COLL (Collegium Pharmaceutical) Accumulated Depreciation : $0.0 Mil (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Collegium Pharmaceutical Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Collegium Pharmaceutical's quarterly accumulated depreciation increased from Sep. 2024 ($0.0 Mil) to Dec. 2024 ($-13.5 Mil) but then stayed the same from Dec. 2024 ($-13.5 Mil) to Mar. 2025 ($0.0 Mil).

Collegium Pharmaceutical's annual accumulated depreciation increased from Dec. 2022 ($-6.3 Mil) to Dec. 2023 ($-9.7 Mil) and increased from Dec. 2023 ($-9.7 Mil) to Dec. 2024 ($-13.5 Mil).

Collegium Pharmaceutical Accumulated Depreciation Historical Data

The historical data trend for Collegium Pharmaceutical's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Collegium Pharmaceutical Accumulated Depreciation Chart

Collegium Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accumulated Depreciation

Get a 7-Day Free Trial

-3.06

-4.70

-6.32

-9.68

-13.53

Collegium Pharmaceutical Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accumulated Depreciation	Get a 7-Day Free Trial															-	-	-	-13.53	-

Collegium Pharmaceutical Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Collegium Pharmaceutical Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Collegium Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (NAS:COLL) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Technology Center Drive, Stoughton, MA, USA, 02072

Website

https://www.collegiumpharma.com

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Executives

Tupper Colleen	officer: EVP & Chief Financial Officer	C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Scott Dreyer	officer: EVP & Chief Commercial Officer	780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Shirley R. Kuhlmann	officer: EVP and General Counsel	780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Thomas B Smith	officer: EVP and Chief Medical Officer	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612
Garen G Bohlin	director	C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Joseph Ciaffoni	director, officer: President and CEO	100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
John Gordon Freund	director	125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Rita J. Balice-gordon	director	C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
John A. Fallon	director	C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
Gwen A Melincoff	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Neil F. Mcfarlane	director	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Richard Malamut	officer: EVP and Chief Medical Officer	100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Alison B Fleming	officer: Vice President, Product Devlp	780 DEDHAM STREET, SUITE 800, CANTON MA 02021